ALLMedicine™ Nephrolithiasis Center

Jun 24th, 2022 - Ovarian torsion is a relatively common gynecological emergency, usually presenting as acute lower abdominal pain. The underlying pathophysiology involves torsion of the ovarian tissue on its pedicle leading to reduced venous return, stromal edema,...

Jun 21st, 2022 - Reference Range Normal values are as follows: Color – Yellow (light/pale to dark/deep amber) Clarity/turbidity – Clear or cloudy pH – 4.5-8 Specific gravity – 1.005-1.025 Glucose - ≤130 mg/d Ketones – None Nitrites – Negative Leukocyte esterase – ...

Jun 21st, 2022 - Reference Range Normal values are as follows: Color – Yellow (light/pale to dark/deep amber) Clarity/turbidity – Clear or cloudy pH – 4.5-8 Specific gravity – 1.005-1.025 Glucose - ≤130 mg/d Ketones – None Nitrites – Negative Leukocyte esterase – ...

Jun 21st, 2022 - Normal values are as follows: Color – Yellow (light/pale to dark/deep amber) Clarity/turbidity – Clear or cloudy pH – 4.5-8 Specific gravity – 1.005-1.025 Glucose - ≤130 mg/d Ketones – None Nitrites – Negative Leukocyte esterase – Negative Bilirub...

Jun 15th, 2022 - For treatment of nephrolithiasis, ambulatory percutaneous nephrolithotomy (aPCNL) is growing in popularity for select patients. The aim of this study was to investigate the safety and efficacy of a set of aPCNL selection criteria as well as search...

Oct 27th, 2016 - Recently published guidelines on the medical management of renal stone disease did not address relevant topics in the field of idiopathic calcium nephrolithiasis, which are important also for clinical research. A steering committee identified 27 q...

Jun 24th, 2022 - Ovarian torsion is a relatively common gynecological emergency, usually presenting as acute lower abdominal pain. The underlying pathophysiology involves torsion of the ovarian tissue on its pedicle leading to reduced venous return, stromal edema,...

Jun 3rd, 2022 - Nephrolithiasis is one of the most common urological diseases, it is a widespread and challenging issue for both patients and healthcare systems. It is responsible for a significant financial and psychological burden, with an increased incidence o...

May 23rd, 2022 - In IUAN patients, the investigator will compare 1. PPAR activation; 2. weight loss; or 3. combination; on urine acid-base parameters relevant to UA stone risk. The investigator will assess the effect of these interventions on fat distribution, ins...

May 4th, 2022 - This study is a pilot exploratory study (preliminary project to assess the use of a kidney sodium coil across a wide spectrum of kidney disease). Approximately 200 patients from the London Health Sciences Regional Renal Program will be recruited. ...

Apr 29th, 2022 - The ureteral stent is one of the most extensively used tools in the field of urology. They are used for aiding post-operative healing of the ureter, visualizing the ureteral during procedures, and alleviating ureteral obstruction (eg. nephrolithia...

Jun 20th, 2022 - Dr Priyadarshini Balasubramanian Patients with type 2 diabetes who received empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, were almost 40% less likely to have a kidney stone than patients who received placebo during a median 1....

May 5th, 2022 - NEW YORK (Reuters Health) - Black patients who visited the emergency department (ED) for nephrolithiasis were more likely than patients of other races to experience delays in surgery regardless of insurance status, researchers found. "We found tha...

Jul 19th, 2021 - NEW YORK (Reuters Health) - Transcatheter aortic-valve implantation (TAVI) is safe and effective for patients with inflammatory bowel disease (IBD), according to what is believed to be the first study to assess TAVI outcomes in this patient popula...

Dec 17th, 2020 - The FDA’s Vaccines and Related Biological Products Advisory Committee has voted 20-0 with 1 abstention to support the benefit-risk profile associated with the coronavirus disease 2019 vaccine mRNA-1273. The proposed use under the Emergency Use Au...

Apr 7th, 2020 - NEW YORK (Reuters Health) - A combination of two approved drugs, leflunomide and hydroxychloroquine, was safe and elicited a clinical response in a phase-2a trial for Sjogren's syndrome. For the 24-week trial, Dr. Joel Adrianus Gijsbert van Roon o...